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Abstract
The emergence of carbapenem-resistant bacterial pathogens is a significant 
and mounting health concern across the globe. At present, carbapenem resistance 
(CR) is considered as one of the most concerning resistance mechanisms and 
mainly found in gram-negative bacteria of the Enterobacteriaceae family. Although 
carbapenem resistance has been recognized in Enterobacteriaceae from last 20 years 
or so, recently it emerged as a global health issue as CR clonal dissemination of 
various Enterobacteriaceae members especially E. coli, and Klebsiella pneumoniae 
are reported from across the globe at an alarming rate. Phenotypically, carbapen-
ems resistance is in due to the two key mechanisms, like structural mutation 
coupled with β-lactamase production and the ability of the pathogen to produce 
carbapenemases which ultimately hydrolyze the carbapenem. Additionally, 
penicillin-binding protein modification and efflux pumps are also responsible for 
the development of carbapenem resistance. Carbapenemases are classified into 
different classes which include Ambler classes A, B, and D. Several mobile genetic 
elements (MGEs) have their potential role in carbapenem resistance like Tn4401, 
Class I integrons, IncFIIK2, IncF1A, and IncI2. Taking together, resistance against 
carbapenems is continuously evolving and posing a significant health threat to 
the community. Variable mechanisms that are associated with carbapenem resis-
tance, different MGEs, and supplementary mechanisms of antibiotic resistance in 
association with virulence factors are expanding day by day. Timely demonstration 
of this global health concern by using molecular tools, epidemiological investiga-
tions, and screening may permit the suitable measures to control this public health 
menace.




1. Antibiotic resistance as a global threat
The global burden of antibiotic resistance is mounting continuously; preferably 
it piles up the pressure on veterinary medicine and on human. The WHO made a 
landmark by promoting and declaring AMR as a global health concern. The agenda of 
global health concerns are at the developmental stages, for example, a book named as 
The Evolving Threat of Antimicrobial Resistance: Options for Action is a precious addition 
to the archive [1]. Currently, the world is experiencing dramatic pre-antibiotic era, and 
many of the untreated infection emerge on a large-scale; clinicians often encounter 
many patients with such infections that normally reported as PDR or MDR bacteria 
by many laboratories and not responding to already available therapeutics. It has 
been estimated that yearly about two million people acquire vulnerable infections just 
because of these antibiotic-resistant pathogens, and as a result of this, about 23,000 
people die according to Centers for Disease Control and Prevention (CDC) [2].
In a historical perspective, antibiotic resistance is a mounting and compelling 
concern. New types of antibiotic-resistant bacteria are taking control of ancient drugs. 
We may be entering the post-antibiotic era, because of increased persistence, spread, 
and the emergence of superbugs. It has been reported that annually, in the USA, about 
99,000 deaths are caused by antibiotic-resistant pathogen-related hospital-acquired 
infections [3]. While in America, the annual death rate is about 50,000 caused by 
two usual HAIs, known as sepsis and pneumonia, which cost around $8 billion to the 
economy of the USA. The patients infected with bacterial strains that are resistant to 
antibiotics must stay in the hospital minimum for 13 days, which adds to 8 million days 
annually. An annual report of the cost of economy loss with regard to a productivity 
loss of around $35 billion has been demonstrated within healthcare settings [3].
2. Causes of antibiotic resistance
Currently, the multifarious causes of resistance constitute many factors includ-
ing improper use and regulations, lack of awareness, aberrant antibiotic usage, the 
use of antibiotics as a growth promoter in livestock as well as in poultry for infection 
control, and online marketing [4]. Fundamentally, the reason behind the resistance 
evolution is the improper and excessive use of antimicrobials. The powerful driv-
ers of antibiotic resistance include infection control standards, sanitation system, 
drug quality, water hygiene systems, diagnostics and therapeutics, and migration 
or travel quarantine. Genetic mutations and exchange of genetic material between 
organisms play a key role in the distribution of antibiotic resistance [5]. MDR 
organisms in hospital wastes are associated with public health illnesses because they 
are ultimately disseminated to humans. In this regard, recently a study has been 
conducted in Pakistan to find the occurrence of ESBL producing K. pneumoniae in 
hospital wastes including hospital sludge and wastewater, operation theater waste. 
They found the significant percentage of extended-spectrum β-lactamases (ESBL) 
producing MDR K. pneumoniae in these wastes [6]. Similarly another study con-
ducted by [7] reported the patterns of antibiotic-resistant K. pneumoniae in clinical 
isolates with special reference to fluoroquinolones, depicting an alarming threat of 
antibiotic resistance among K. pneumoniae-related nosocomial infections.
3. Carbapenems
Carbapenems are effective β-lactam antimicrobials and have very potent efficacy 
against many ESBL-producing bacteria and are also administered intravenously. In 
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order to treat bacterial infections, carbapenems are considered as the most reliable 
and the last resort class of antimicrobials. Carbapenem agent has a very unique 
structure, usually defined by carbapenem coupled to B-lactam ring, which provide 
protection against the majority of b-lactamases as well as metallo-b-lactamases, and 
thus possess extended antibacterial activity [8]. Carbapenems work by penetrating 
the cell wall of bacteria, binding with penicillin-binding proteins (PBPs), and result 
in inactivation of intracellular autolytic inhibitor enzymes, ultimately killing the 
bacterial cell.
In addition, carbapenems mainly target “transpeptidase inhibition enzyme” 
during bacterial cell wall synthesis, preventing peptide cross-linking activity, 
leading to enhanced autolytic activity, and thus resulting in cell death. Therefore, 
carbapenems are considered as effective antimicrobials to treat life-threatening 
and invasive infections due to their “concentration-independent killing effect” on 
infecting bacteria [9, 10].
4. Carbapenemases
Carbapenemases are versatile b-lactamases, having the capability to hydrolyze 
carbapenems, cephalosporins, penicillins, and monobactams. Carbapenemases 
typically belong to two molecular families, namely, “metallo-carbapenemases” in 
which activity is inhibited by EDTA, used zinc molecule at their active sites, and 
“serine-based carbapenemases” in which activity is not inhibited by EDTA rather 
used serine residues at their active sites and inactivated through β-lactamase inhibi-
tors like tazobactam and clavulanic acid [11].
β-Lactamases are classified based on two properties: functional and molecular 
ones. Functional classification was proposed by a scientist “Bush” in 1988, who clas-
sified β-lactamases into four functional groups namely, groups 1–4. Carbapenems 
fall under subgroup the 2f and group 3 [12]. Later on another scientist, Rasmussen, 
suggested that group 3 can be further divided into three functional subgroups on 
the basis of substrate specificity [13].
The molecular classification was proposed by scientist “Frere” and col-
leagues, who classified carbapenemases into class A, class B, and class D car-
bapenemases (Table 1).
Class A carbapenemases require a serine active site at position number 70 in 
Ambler numbering system, fall under the group 2f, and have the ability to hydro-
lyze carbapenems, penicillins, aztreonam, and cephalosporins [14].
Classification Enzymes Common bacteria
Class A SME, NMC, KPC, IMI, GES All Enterobacteriaceae, rarely P. aeruginosa
Class B VIM, SPM, GIM, IMP Acinetobacter species, P. aeruginosa, 
Enterobacteriaceae
Subclass B1 VIM-2, IMP-1, SPM-1, CcrA 
and BcII
Subclass B2 Sfh-1, CphA
Subclass B3 Gob-1, FEZ-1, CAU-1 & L1
Class D OXA Acinetobacter species
Table 1. 
Molecular classification scheme of carbapenemases [16].
Pathogenic Bacteria
4
Class B metallo-B-lactamases require a zinc ion at their active sites and have 
the ability to hydrolyze carbapenems, penicillins, and cephalosporins but do not 
hydrolyze aztreonam [15].
Class D carbapenemases were firstly described in 1993; among these class D 
OXA β-lactamases are the most important and were anciently named as penicillin-
ases and have the ability to hydrolyze oxacillin, penicillin, cloxacillin, and ceftazi-
dime but do not hydrolyze imipenem [11].
5. The emergence of carbapenem resistance
Carbapenem resistance is a leading and major public health concern around the 
globe. It mainly occurs among the Enterobacteriaceae family, particularly in health-
care settings. In the UK and the USA, carbapenem-resistant enteric bacterial strain 
has been identified and isolated from such patients who recently received medical 
care in Bangladesh, Pakistan, and India. Such strains possess a gene called New 
Delhi metallo-β-lactamases (NDM), responsible for producing metallo-β-lactamase 
enzyme that causes hydrolysis of carbapenems [17].
Factors that play a critical role in the emergence of carbapenem resistance are 
improper antibiotic prescription, uncontrolled public access to antimicrobials, poor 
sales regulation, lack of infection control measures within healthcare centers, the 
use of sub-therapeutic doses in agricultural settings [18].
In gram-negative bacteria, the development of carbapenem resistance (particu-
larly in the presence of carbapenemases) is a leading factor associated with the emer-
gence of MDR pathogens which may ultimately lead to the development of pandrug 
resistant (PDR) bacterial strains. Undoubtedly, among the carbapenemase-producing 
organisms, resistance to the last resort agents rapidly emerge and spread particularly 
when such agents are used in healthcare centers [18]. It has also been demonstrated 
that this carbapenem-resistant-nosocomial pathogens continually emerge, thus 
accruing more carbapenem resistance determinants, mechanisms, as well as carbape-
nem encoding genes that ultimately lead to increase carbapenem MICs ruling out yet 
the best therapeutic choice against such carbapenemase producers [18].
6. Mechanisms of carbapenem resistance
The emergence of resistance against these antibiotics reflects a growing health 
concern around the globe. Carbapenem resistance is mainly caused by two basic 
mechanisms including the production of carbapenemases (carbapenem-hydrolyz-
ing enzymes) and B-lactamase activity coupled with structural mutations (ESBLs 
and AmpC cephalosporinases) [19, 20] (Figure 1).
Carbapenem resistance can be developed either due to acquired or intrinsic 
resistance mechanisms or sometimes both, since the bacteria have acquired numer-
ous resistance mechanisms including mutations in the target site, efflux pumps, and 
enzymatic inactivation. Among these, enzymatic inactivation [acquired carbapen-
emases (plasmid-mediated)] is the most emerging and well-established mechanism. 
Acquired carbapenem resistance mechanisms include (1) destruction of carbapen-
ems which are resistant to hydrolysis by plasmid AmpCs in conjunction with ESBL 
enzymes, contributing insusceptibility towards carbapenem agent [21]; (2) transfer 
of ESBL genes between the organisms; and (3) porin mutation with expression 
modulation. Loss of OprD porin and efflux pump overexpression is a usual mecha-
nism of carbapenem resistance in the case of Pseudomonas aeruginosa [22]. Intrinsic 
carbapenem resistance mechanism includes reduced uptake (due to altered porin 
channels) and reduced outer membrane permeability of B-lactam drugs [16].
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Several mobile genetic elements have their potential role in carbapenem resis-
tance like Tn4401, Class I integrons, IncFIIK2, IncF1A, and IncI2 [17]. Transposon 
Tn4401 contains tnpR and tnpA genes, coding for “resolvase” and “transposase,” 
respectively, and is mainly associated with blaKPC-2 type [23]. Plasmids IncFIIK2, 
IncF1A, and IncI2 belong to ST101 K. pneumoniae type-2 found from bloodstream 
infections in the Asian region particularly in India.
7. Drivers of carbapenem resistance
To date, drivers for the acquisition of Carbapenem resistance among gram-
negative bacteria have not been emphasized. But some of the known drivers for 
carbapenem resistance are prior long-term use of metronidazole and imipenem 
drugs in hospital settings, prior long-term hospital stays, and the presence of biliary 
drain catheters. It has been described that the disruption of normal flora by met-
ronidazole increases the frequency of translocation, hence promoting carbapenem 
resistance among Enterobacteriaceae [24].
It has also been demonstrated that carbapenem resistance accelerated, once the 
gene for these enzymes became associated with acquired genetic elements like inte-
grons and plasmids [25]. Thus the circulation of carbapenem-resistant genes among 
different strains isolated from clinic and hospital sewerage system coupled with 
the transfer of such genes by bacteriophage carrying Β-lactamases genes coding 
for OXA-B-lactamases is now been considered as potential drivers for the increased 
spread and emergence of Carbapenem resistance [26].
8. Carbapenem-resistant Enterobacteriaceae: a mounting health concern
The Enterobacteriaceae is responsible for causing healthcare-related infections. 
Recent studies reported by the regulatory authority “Centre for Disease Control 
Figure 1. 
Mechanism of carbapenem resistance in Enterobacteriaceae. (1) Reduced membrane permeability through 
modified porins, expression loss or shift in porin proteins in outer-membrane; (2) enzymatic inactivation by 




and Prevention” reveal that more than 21.3% of healthcare-related infections 
are due to Enterobacteriaceae [27]. Spread and the emergence of Carbapenem-
resistant Enterobacteriaceae is a mounting health concern around the globe [28]. 
Regulatory authority “Centre for Disease Control and Prevention” defines CRE as 
“Enterobacteriaceae that seems to be tested as resistant to any carbapenem agent 
including ertapenem or may demonstrate as carbapenemase production through 
molecular or phenotypic assay” [29].
The emergence of carbapenem resistance among Enterobacteriaceae (CRE) 
possessing additional resistance genes to a variety of antimicrobial classes had 
led to the creation of organisms nearly resistant to all available therapeutics [30]. 
Carbapenem-resistant Enterobacteriaceae are a family of bacteria, responsible for 
causing significant mortality and morbidity, and hence are very difficult to treat. 
Among the Enterobacteriaceae, E. coli and Klebsiella species can easily become 
carbapenem resistant. CRE infections commonly occur in healthcare and hospital 
settings as well as in nursing homes, while the patients on-going long-term antibi-
otic treatment are also highly susceptible to these CRE infections [31].
Epidemiological data on carbapenemase-producing carbapenem-resistant 
Enterobacteriaceae (CP-CRE) varies country to country. An important carbapene-
mase-producing carbapenem resistance (KPC) was the first identified carbapen-
emase in the USA in 1996, and the prevalence is distributed unevenly among the 
US states [32]. Since epidemiology of CRE varies differently, so in this regard, KPC 
is endemic in Israel, while VIM, IPM, NDM, and OXA-48 carbapenemases are 
endemic in Greece, Japan, India, and Turkey, respectively, and are also dissemi-
nated successfully around the globe [33]. The continuous movement of subjects 
infected or colonized with CP-CRE in conjunction with the continuous exposure of 
these subjects to medical care is a significant contributor to the spread of CP-CRE 
[34]. Therefore, the decisive detection of CP-CRE may be the initial step to combat 
such a mounting health concern [29].
9. Treatment options
Since CRE infections are very difficult to treat, some of the treatment options 
for addressing the threat of “Carbapenem-resistant Enterobacteriaceae” include 
tigecycline, polymyxins, aminoglycosides, fosfomycin, meropenem/vaborbactam, 
and ceftazidime/avibactam. Combinations of B-lactamase are also available and are 
safer and more effective for treating CRE infections. It has been reported that poly-
myxin monotherapy can also lead to the emergence of resistance; therefore, poly-
myxin in combination with carbapenems must be administered in an appropriate 
dose [35]. Similar is the case with fosfomycin. The use of fosfomycin intravenously 
is recommended for urinary tract infections [36]. Clinicians should be vigilant in 
exploring new treatment options as well as for detection of CRE infections. Many of 
the new treatment options are in process, but none of them represent a magic bullet 
to address this concerned threat.
10. Conclusion
The rapid spread of carbapenem resistance as well as carbapenem-resistant 
Enterobacteriaceae into the community is a growing and emerging threat to public 
health. Despite of the large efforts being made to control this public menace, 
it is very essential to look for some definite solution which still seems to be far 
off. Until a potential alternative solution to overcome this problem is found, 
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application of infection control measures whenever CR is detected, rationaliza-
tion of antibiotic use as well as ensuring active surveillance system may be some 
steps to control this menace.
An interdisciplinary and global assess should be examined for the formula-
tion of new diagnostic and screening tools. In this regard, alternative strategies to 
antibiotics like the use of phage therapy and probiotics can reduce this resistance 
burden. The spread of resistance can be minimized by immunization, application 
of infection control measures, rationalization of antibiotic usage, proper screening 
and treatment, and education and awareness programs. At global, national, and 
regional level, tracking and bio-surveillance system and preventive approaches of 
MDR and AMR pathogens can control this “global resistome.”
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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